BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-4.41%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.21B
AUM Growth
+$6.21B
(-11%)
Cap. Flow
-$226M
Cap. Flow
% of AUM
-3.64%
Top 10 Holdings %
Top 10 Hldgs %
40.63%
Holding
166
New
10
Increased
37
Reduced
80
Closed
12
Top Buys
| 1 |
Elevance Health
ELV
|
$31.1M |
| 2 |
UnitedHealth
UNH
|
$24.2M |
| 3 |
Cigna
CI
|
$21.5M |
| 4 |
Humana
HUM
|
$20.8M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$10.5M |
Top Sells
| 1 |
Medtronic
MDT
|
$60.3M |
| 2 |
Inspire Medical Systems
INSP
|
$56.9M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$32.8M |
| 4 |
Charles River Laboratories
CRL
|
$16.7M |
| 5 |
Thermo Fisher Scientific
TMO
|
$15M |
Sector Composition
| 1 | Healthcare | 99.13% |
| 2 | Industrials | 0.77% |
| 3 | Energy | 0.04% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
DexCom
DXCM
$30.9B
| $64M | 1.03% |
685,733
-75,983
| -10% | -$7.09M |
|
27
Pacific Biosciences
PACB
$378M
| $60.5M | 0.97% |
7,245,188
-297,641
| -4% | -$2.49M |
|
28
Penumbra
PEN
$10.5B
| $57.4M | 0.92% |
237,252
+3,032
| +1% | +$733K |
|
29
Celldex Therapeutics
CLDX
$1.57B
| $52.3M | 0.84% |
1,900,000
+100,000
| +6% | +$2.75M |
|
30
Molina Healthcare
MOH
$9.6B
| $52M | 0.84% |
158,438
-5,900
| -4% | -$1.93M |
|
31
Exelixis
EXEL
$9.95B
| $51.9M | 0.84% |
2,375,925
-158,075
| -6% | -$3.45M |
|
32
Align Technology
ALGN
$9.59B
| $51M | 0.82% |
166,886
-4,254
| -2% | -$1.3M |
|
|
SWAV
33
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $50.6M | 0.82% |
254,279
-16,247
| -6% | -$3.23M |
|
|
34
Medtronic
MDT
$118B
| $50.3M | 0.81% |
641,492
-769,000
| -55% | -$60.3M |
|
35
Idexx Laboratories
IDXX
$50.7B
| $50M | 0.81% |
114,441
| – | – |
|
36
Bio-Rad Laboratories Class A
BIO
$7.8B
| $48.2M | 0.78% |
134,330
-203
| -0.2% | -$72.8K |
|
|
ACCD
37
DELISTED
Accolade, Inc. Common Stock
ACCD
| $47.9M | 0.77% |
4,527,923
+6,864
| +0.2% | +$72.6K |
|
38
MacroGenics
MGNX
$121M
| $45.7M | 0.74% |
9,803,313
+193,400
| +2% | +$901K |
|
39
Veeva Systems
VEEV
$44.4B
| $45.6M | 0.73% |
224,100
-46,946
| -17% | -$9.55M |
|
|
40
Charles River Laboratories
CRL
$7.99B
| $44.9M | 0.72% |
229,342
-85,171
| -27% | -$16.7M |
|
41
Tandem Diabetes Care
TNDM
$834M
| $44.5M | 0.72% |
2,142,769
+49,835
| +2% | +$1.04M |
|
42
Axsome Therapeutics
AXSM
$6.09B
| $44.1M | 0.71% |
631,487
+57,124
| +10% | +$3.99M |
|
43
Eli Lilly
LLY
$661B
| $43.8M | 0.71% |
81,541
-13,614
| -14% | -$7.31M |
|
44
Insulet
PODD
$24.2B
| $42.2M | 0.68% |
264,359
-59,235
| -18% | -$9.45M |
|
45
Arvinas
ARVN
$580M
| $41.7M | 0.67% |
2,125,200
-1,800
| -0.1% | -$35.4K |
|
46
Relay Therapeutics
RLAY
$709M
| $41.1M | 0.66% |
4,885,000
+714,200
| +17% | +$6.01M |
|
47
CRISPR Therapeutics
CRSP
$4.82B
| $40.8M | 0.66% |
898,400
-900
| -0.1% | -$40.9K |
|
48
HCA Healthcare
HCA
$95.4B
| $38.3M | 0.62% |
155,643
-4,872
| -3% | -$1.2M |
|
|
49
Cigna
CI
$80.2B
| $35.9M | 0.58% |
125,502
+75,103
| +149% | +$21.5M |
|
50
Jazz Pharmaceuticals
JAZZ
$7.99B
| $34.5M | 0.56% |
266,226
-22,553
| -8% | -$2.92M |
|